Matt Gline, Roivant Sciences CEO (Photo by John Sciulli/Getty Images for GLG)
November 12, 2022 01:02 PM ESTUpdated November 14, 06:53 AM
People
Pharma

Roivant cuts 12% of staff in cost-sav­ing move

Drew Armstrong

Executive Editor

Roivant Sci­ences cut 12% of its work­force on Thurs­day, the com­pa­ny told End­points News, mak­ing it the lat­est biotech to trim staff amid an in­dus­try …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times